• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Edgewise Therapeutics Inc (NQ: EWTX )

    29.65 +10.58 (+55.48%)
    Streaming Delayed Price Updated: 11:49 AM EDT, Sep 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 7,581,062
    Open 25.75
    Bid (Size) 29.55 (2)
    Ask (Size) 29.68 (4)
    Prev. Close 19.07
    Today's Range 24.84 - 29.71
    52wk Range 5.120 - 23.50
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
    Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy, showing the drug was well tolerated with reductions in LVOT... 
    Via Benzinga
    Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday
    Via Benzinga

    Performance

    YTD
    +169.54%
    +169.54%
    1 Month
    +57.54%
    +57.54%
    3 Month
    +76.38%
    +76.38%
    6 Month
    +76.80%
    +76.80%
    1 Year
    +380.55%
    +380.55%

    More News

    Read More
    Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
    Via Investor's Business Daily
    Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
    From Edgewise Therapeutics
    Via Business Wire
    EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From Edgewise Therapeutics
    Via Business Wire
    7 Small-Cap Stocks to Buy for Large-Scale Gains
    Via InvestorPlace
    Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
    Via Investor's Business Daily
    Topics Government
    Exposures Political
    Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
    Via Investor's Business Daily
    Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
    Via Investor's Business Daily
    Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
    From Edgewise Therapeutics
    Via Business Wire
    EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
    Via Benzinga
    Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
    From Edgewise Therapeutics
    Via Business Wire
    Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
    From Edgewise Therapeutics
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.